Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Nov 14, 2016. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q3 2016. Go to the latest filing (Q3 2026)

7.0B USDQ3 2016
Total value of stock positions
7.0B USD
Positions
43
Share of the ten largest
69.7%

The ten largest positions Q3 2016

  1. Cheniere Energy Inc 17.4%▼ −6.7%
  2. Viasat Inc 12.3%unchanged
  3. Synchrony Financial 7.0%new
  4. Allergan PLC 6.6%unchanged
  5. Antero Res Corp 5.6%unchanged
  6. Pbf Energy Inc 5.1%▲ +47.8%
  7. Dell Technologies 4.5%new
  8. Twenty First Centy Fox Inc 4.4%▲ +65.6%
  9. Theravance Biopharma Inc 3.8%unchanged
  10. PayPal 2.9%▼ −11.7%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q3 2016

Positions Q3 2016 per 13F filing, 43 of 43
Symbol Weight Shares Reported value Change Held since
Cheniere Energy Inc 17.4% 27,842,957 1.2B USD −6.7% reduced Q1 2014 11 quarters
Viasat Inc 12.3% 11,533,137 860.9M USD unchanged Q2 2013 or earlier 14 quarters
SYF Synchrony Financial 7.0% 17,565,000 491.8M USD new Q3 2016 1 quarter
Allergan PLC 6.6% 2,001,978 461.1M USD unchanged Q1 2016 3 quarters
Antero Res Corp 5.6% 14,505,881 390.9M USD unchanged Q3 2014 9 quarters
Pbf Energy Inc 5.1% 15,724,175 356.0M USD +47.8% increased Q3 2013 13 quarters
DELL Dell Technologies 4.5% 6,652,459 318.0M USD new Q3 2016 1 quarter
Twenty First Centy Fox Inc 4.4% 12,746,469 308.7M USD +65.6% increased Q3 2015 5 quarters
Theravance Biopharma Inc 3.8% 7,350,991 266.4M USD unchanged Q2 2014 10 quarters
PYPL PayPal 2.9% 5,000,000 204.9M USD −11.7% reduced Q3 2015 5 quarters
Twenty First Centy Fox Inc 2.6% 7,278,100 180.1M USD unchanged Q3 2015 5 quarters
Innoviva Inc 2.3% 14,931,483 164.1M USD −15.2% reduced Q1 2016 3 quarters
Veritiv Corp 2.2% 3,044,385 152.7M USD unchanged Q3 2014 9 quarters
Keryx Biopharmaceuticals Inc 2.0% 25,791,678 137.0M USD unchanged Q1 2014 11 quarters
Northstar Asset Mgmt Group I 1.8% 9,913,654 128.2M USD new Q3 2016 1 quarter
Olin Corp 1.8% 6,181,302 126.8M USD −42.4% reduced Q3 2015 5 quarters
Vmware Inc 1.7% 1,603,889 117.6M USD −28.8% reduced Q1 2016 3 quarters
Atara Biotherapeutics Inc 1.6% 5,359,632 114.6M USD unchanged Q4 2014 8 quarters
Forward Pharma A/S 1.6% 5,367,300 112.7M USD unchanged Q4 2014 8 quarters
Liberty Interactive Corp 1.4% 2,469,533 98.5M USD unchanged Q2 2016 2 quarters
Colony Cap Inc 1.2% 4,445,936 81.0M USD new Q3 2016 1 quarter
Chipmos Tech Bermuda Ltd 1.1% 3,751,853 74.3M USD unchanged Q2 2013 or earlier 14 quarters
Northstar Rlty Fin Corp 1.0% 5,498,261 72.4M USD new Q3 2016 1 quarter
Klx Inc 1.0% 2,000,000 70.4M USD unchanged Q1 2015 7 quarters
Silver Run Acquisition Corp 0.8% 3,750,000 59.1M USD unchanged Q2 2016 2 quarters
American Intl Group Inc 0.8% 2,594,317 55.0M USD +1.7% increased Q2 2013 or earlier 14 quarters
Novagold Res Inc 0.8% 9,500,000 53.2M USD unchanged Q2 2013 or earlier 14 quarters
Liberty Media Corp Delaware 0.7% 2,994,010 52.0M USD unchanged Q2 2016 2 quarters
Office Depot Inc 0.7% 13,000,000 46.4M USD new Q3 2016 1 quarter
Cascadian Therapeutics Inc 0.6% 25,000,000 41.0M USD unchanged Q2 2016 2 quarters
Conyers Pk Acquisition 0.5% 3,712,500 37.1M USD new Q3 2016 1 quarter
Paratek Pharmaceuticals Inc 0.4% 2,044,498 26.6M USD unchanged Q4 2014 8 quarters
Saban Cap Acquisition Corp 0.3% 2,326,500 23.5M USD new Q3 2016 1 quarter
Credit Accep Corp Mich 0.3% 100,000 20.1M USD unchanged Q2 2016 2 quarters
RUN Sunrun 0.3% 2,848,082 17.9M USD unchanged Q3 2015 5 quarters
Kindred Biosciences Inc 0.2% 3,011,584 15.0M USD −0.1% reduced Q4 2013 12 quarters
Liberty Media Corp Delaware 0.2% 800,000 14.0M USD unchanged Q2 2016 2 quarters
Orexigen Therapeutics Inc 0.1% 2,226,839 7.4M USD new Q3 2016 1 quarter
Tobira Therapeutics Inc < 0.1% 160,829 6.4M USD new Q3 2016 1 quarter
Trilogy Metals Inc New < 0.1% 10,600,758 5.8M USD new Q3 2016 1 quarter
Citigroup Inc < 0.1% 102,553,207 5.4M USD unchanged Q2 2013 or earlier 14 quarters
Silver Run Acquisition Corp < 0.1% 950,000 5.3M USD −24.0% reduced Q2 2016 2 quarters
Conyers Pk Acquisition < 0.1% 1,237,500 1.4M USD new Q3 2016 1 quarter

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 1 position in convertible bonds and bonds worth 40.5M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Inc principal 48.2M USD 40.5M USD

Breakdown by sector

  • Financials 10.0%
  • Technology 4.5%
  • Industrials 0.3%
  • not in our coverage 85.2%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close